# Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

> **NCT07036133** · PHASE1 · RECRUITING · sponsor: **Acrotech Biopharma Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Hematologic Malignancies

## Interventions

- **DRUG:** Pralatrexate Injection

## Key facts

- **NCT ID:** NCT07036133
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-28
- **Primary completion:** 2027-02
- **Final completion:** 2027-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07036133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07036133, "Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07036133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*